Rheonix COVID-19™ MDx Assay Receives Expanded FDA Emergency Use Authorization to Include Saliva Home Collection Kit
ITHACA, N.Y. — Rheonix Inc. announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx Assay to include home collection using the Rheonix Laboratories COVID-19 PCR Test Saliva Home Collection Kit. Rheonix’s fully automated sample-to-answer COVID-19 assay received its initial EUA… Read More »
Rheonix Laboratories LLC is a New York State-permitted CLIA laboratory that provides easy, streamlined testing for organizations and community members
ITHACA, N.Y. — Rheonix Inc., a manufacturer of a highly advanced microfluidic molecular testing platform, announced the opening of Rheonix Laboratories LLC, a CLIA-certified clinical laboratory located in Ithaca, New York. Rheonix Laboratories is permitted by New York State to provide COVID-19 PCR testing and results, and will be partnering with… Read More »
New addition to Rheonix leadership adds expertise in infectious diseases and global epidemic response
ITHACA, N.Y. — Rheonix Inc., an innovative leader in highly multiplexed pathogen detection, announced the appointment of Stephen J. Thomas, M.D., as Chief Medical Officer and member of the Rheonix Board of Directors.
"I am delighted to welcome Dr. Thomas to the Rheonix Board and as our Chief Medical Officer," said Greg Galvin, President, CEO and Chairman of… Read More »
Low-cost, scalable, sample-to-answer system provides flexibility and true walk-away testing
ITHACA, N.Y. — Rheonix Inc., an innovative leader in highly multiplexed pathogen detection, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of its automated Encompass MDx® Workstation, along with its STI TriPlex™ Assay and Male Urine Collection Kit for the detection of sexually transmitted infections (STI).
“Rheonix is pleased to announce our FDA 510(k) approval for a… Read More »